These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31673932)

  • 21. Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.
    Delsing Malmberg E; Johansson Alm S; Nicklasson M; Lazarevic V; Ståhlman S; Samuelsson T; Lenhoff S; Asp J; Ehinger M; Palmqvist L; Brune M; Fogelstrand L
    Leuk Lymphoma; 2019 Feb; 60(2):409-417. PubMed ID: 30068244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NPM1 for MRD? Droplet Like It's Hot!
    Wertheim GBW; Bagg A
    J Mol Diagn; 2017 Jul; 19(4):498-501. PubMed ID: 28645444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
    Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
    Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.
    Hirsch P; Lambert J; Bucci M; Deswarte C; Boudry A; Lambert J; Fenwarth L; Micol JB; Terré C; Celli-Lebras K; Thomas X; Dombret H; Duployez N; Preudhomme C; Itzykson R; Delhommeau F
    Blood Cancer J; 2024 Jun; 14(1):97. PubMed ID: 38871702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurable residual disease testing for personalized treatment of acute myeloid leukemia.
    Ehinger M; Pettersson L
    APMIS; 2019 May; 127(5):337-351. PubMed ID: 30919505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological and clinical consequences of NPM1 mutations in AML.
    Heath EM; Chan SM; Minden MD; Murphy T; Shlush LI; Schimmer AD
    Leukemia; 2017 Apr; 31(4):798-807. PubMed ID: 28111462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
    Balagopal V; Hantel A; Kadri S; Steinhardt G; Zhen CJ; Kang W; Wanjari P; Ritterhouse LL; Stock W; Segal JP
    PLoS One; 2019; 14(10):e0224097. PubMed ID: 31658273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.
    Luthra R; Patel KP; Reddy NG; Haghshenas V; Routbort MJ; Harmon MA; Barkoh BA; Kanagal-Shamanna R; Ravandi F; Cortes JE; Kantarjian HM; Medeiros LJ; Singh RR
    Haematologica; 2014 Mar; 99(3):465-73. PubMed ID: 24142997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytoplasmic expression of nucleophosmin 1 as a marker for diagnosing residual disease of acute myeloid leukemia.
    Dai Q; Ren Y
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):205-11. PubMed ID: 23591014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of NPM1 Mutations in Acute Myeloid Leukemia by using Drop-Off Droplet Digital PCR and its Clinical Application.
    Jin Y; Xu ZJ; Yu D; Xia PH; Yao DM; Yuan Q; Li T; Xiang HL; Ma JC; Wen XM; Lin J; Qian J
    Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
    Yang F; Anekpuritanang T; Press RD
    Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.
    Hantel A; Stock W; Kosuri S
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):636-647. PubMed ID: 30006258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous detection of mutations and copy number variation of NPM1 in the acute myeloid leukemia using multiplex ligation-dependent probe amplification.
    Marcinkowska-Swojak M; Handschuh L; Wojciechowski P; Goralski M; Tomaszewski K; Kazmierczak M; Lewandowski K; Komarnicki M; Blazewicz J; Figlerowicz M; Kozlowski P
    Mutat Res; 2016 Apr; 786():14-26. PubMed ID: 26894557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic impact of early minimal residual disease combined with complete molecular evaluation in acute myeloid leukemia with mutated
    Memoli M; Genthon A; Favale F; Lapusan S; Johnson N; Adaeva R; Deswarte C; Battipaglia G; Malard F; Duléry R; Brissot E; Banet A; Van de Wyngaert Z; Mohty M; Delhommeau F; Legrand O; Hirsch P
    Leuk Lymphoma; 2022 Sep; 63(9):2171-2179. PubMed ID: 35459427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations.
    Thol F; Kölking B; Damm F; Reinhardt K; Klusmann JH; Reinhardt D; von Neuhoff N; Brugman MH; Schlegelberger B; Suerbaum S; Krauter J; Ganser A; Heuser M
    Genes Chromosomes Cancer; 2012 Jul; 51(7):689-95. PubMed ID: 22454318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of the nucleophosmin gene mutations in acute myelogenous leukemia through RT-PCR and polyacrylamide gel electrophoresis.
    Calvo KL; Ojeda MJ; Ammatuna E; Lavorgna S; Ottone T; Targovnik HM; Lo-Coco F; Noguera NI
    Eur J Haematol; 2009 Jan; 82(1):69-72. PubMed ID: 18801061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.
    Onecha E; Linares M; Rapado I; Ruiz-Heredia Y; Martinez-Sanchez P; Cedena T; Pratcorona M; Oteyza JP; Herrera P; Barragan E; Montesinos P; Vela JAG; Magro E; Anguita E; Figuera A; Riaza R; Martinez-Barranco P; Sanchez-Vega B; Nomdedeu J; Gallardo M; Martinez-Lopez J; Ayala R
    Haematologica; 2019 Feb; 104(2):288-296. PubMed ID: 30093399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of methods for detection of NPM1 gene mutations in acute myeloid leukemia].
    Li ZP; Zhang X; Zhao XM; Li QG; Chen YM; Lu QY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):999-1004. PubMed ID: 21867632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia.
    Ottone T; Ammatuna E; Lavorgna S; Noguera NI; Buccisano F; Venditti A; Giannì L; Postorino M; Federici G; Amadori S; Lo-Coco F
    J Mol Diagn; 2008 May; 10(3):212-6. PubMed ID: 18403613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MRD evaluation of AML in clinical practice: are we there yet?
    Freeman SD; Hourigan CS
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):557-569. PubMed ID: 31808906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.